Which has stronger valuation and earnings, PYPD or ELMD?

Electromed has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A Electromed $71.75M 5.31 $5.15M $1.17 39.31

Is PYPD or ELMD more profitable?

Electromed has a net margin of 11.34% compared to PolyPid's net margin of 0.00%. Electromed's return on equity of 15.71% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Electromed 11.34% 15.71% 13.37%

Which has better valuation and earnings, PYPD or CARL?

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A Carlsmed $50.51M 6.52 -$29.63M -$2.51 N/A

Is PYPD or CARL more profitable?

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Carlsmed -57.76% -60.74% -29.84%

Does the media prefer PYPD or CARL?

In the previous week, PolyPid had 1 more articles in the media than Carlsmed. MarketBeat recorded 3 mentions for PolyPid and 2 mentions for Carlsmed. PolyPid's average media sentiment score of 1.54 beat Carlsmed's score of 0.94 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Carlsmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PYPD or CV?

CapsoVision has higher revenue and earnings than PolyPid. CapsoVision is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A CapsoVision $13.55M 22.93 -$25.32M -$2.34 N/A

Is PYPD or CV more profitable?

PolyPid has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% CapsoVision -198.87% N/A -136.03%

Does the media favor PYPD or CV?

In the previous week, CapsoVision had 5 more articles in the media than PolyPid. MarketBeat recorded 8 mentions for CapsoVision and 3 mentions for PolyPid. CapsoVision's average media sentiment score of 1.75 beat PolyPid's score of 1.54 indicating that CapsoVision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CapsoVision 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PYPD or SGHT more profitable?

PolyPid has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Sight Sciences -46.83% -52.34% -28.49%

Does the media prefer PYPD or SGHT?

In the previous week, Sight Sciences had 10 more articles in the media than PolyPid. MarketBeat recorded 13 mentions for Sight Sciences and 3 mentions for PolyPid. PolyPid's average media sentiment score of 1.54 beat Sight Sciences' score of -0.15 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sight Sciences 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TMCI or PYPD?

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 3 articles in the media. PolyPid's average media sentiment score of 1.54 beat Treace Medical Concepts' score of 1.14 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

PolyPid (PYPD) Competitors

$5.04 -0.19 (-3.63%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$5.05 +0.01 (+0.20%)

As of 07:54 AM Eastern

Compare

PYPD vs. ELMD, CARL, CV, SGHT, and TMCI

Should you buy PolyPid stock or one of its competitors? MarketBeat compares PolyPid with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PolyPid include Electromed (ELMD), Carlsmed (CARL), CapsoVision (CV), Sight Sciences (SGHT), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry.

How does PolyPid compare to Electromed?

PolyPid (NASDAQ:PYPD) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PolyPid currently has a consensus price target of $11.67, indicating a potential upside of 131.48%. Electromed has a consensus price target of $37.50, indicating a potential downside of 18.46%. Given PolyPid's higher possible upside, research analysts clearly believe PolyPid is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Electromed has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Electromed	$71.75M	5.31	$5.15M	$1.17	39.31

PolyPid has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Electromed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Electromed has a net margin of 11.34% compared to PolyPid's net margin of 0.00%. Electromed's return on equity of 15.71% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Electromed	11.34%	15.71%	13.37%

In the previous week, PolyPid had 3 more articles in the media than Electromed. MarketBeat recorded 3 mentions for PolyPid and 0 mentions for Electromed. PolyPid's average media sentiment score of 1.54 beat Electromed's score of 1.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Very Positive
Electromed	Positive

Summary

Electromed beats PolyPid on 10 of the 16 factors compared between the two stocks.

How does PolyPid compare to Carlsmed?

PolyPid (NASDAQ:PYPD) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 12.9% of Carlsmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Carlsmed	-57.76%	-60.74%	-29.84%

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Carlsmed	$50.51M	6.52	-$29.63M	-$2.51	N/A

In the previous week, PolyPid had 1 more articles in the media than Carlsmed. MarketBeat recorded 3 mentions for PolyPid and 2 mentions for Carlsmed. PolyPid's average media sentiment score of 1.54 beat Carlsmed's score of 0.94 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Carlsmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PolyPid currently has a consensus target price of $11.67, indicating a potential upside of 131.48%. Carlsmed has a consensus target price of $18.75, indicating a potential upside of 54.83%. Given PolyPid's stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

PolyPid beats Carlsmed on 9 of the 13 factors compared between the two stocks.

How does PolyPid compare to CapsoVision?

PolyPid (NASDAQ:PYPD) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

CapsoVision has higher revenue and earnings than PolyPid. CapsoVision is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
CapsoVision	$13.55M	22.93	-$25.32M	-$2.34	N/A

In the previous week, CapsoVision had 5 more articles in the media than PolyPid. MarketBeat recorded 8 mentions for CapsoVision and 3 mentions for PolyPid. CapsoVision's average media sentiment score of 1.75 beat PolyPid's score of 1.54 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CapsoVision	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PolyPid presently has a consensus price target of $11.67, suggesting a potential upside of 131.48%. CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 36.66%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 2.3% of CapsoVision shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
CapsoVision	-198.87%	N/A	-136.03%

Summary

PolyPid beats CapsoVision on 9 of the 15 factors compared between the two stocks.

How does PolyPid compare to Sight Sciences?

PolyPid (NASDAQ:PYPD) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

PolyPid has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Sight Sciences	-46.83%	-52.34%	-28.49%

PolyPid currently has a consensus target price of $11.67, indicating a potential upside of 131.48%. Sight Sciences has a consensus target price of $8.25, indicating a potential upside of 54.49%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts clearly believe PolyPid is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 30.4% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Sight Sciences had 10 more articles in the media than PolyPid. MarketBeat recorded 13 mentions for Sight Sciences and 3 mentions for PolyPid. PolyPid's average media sentiment score of 1.54 beat Sight Sciences' score of -0.15 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sight Sciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PolyPid has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Sight Sciences	$77.36M	3.76	-$38.43M	-$0.71	N/A

PolyPid has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

Summary

Sight Sciences beats PolyPid on 9 of the 15 factors compared between the two stocks.

How does PolyPid compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to Treace Medical Concepts' net margin of -29.44%. Treace Medical Concepts' return on equity of -67.04% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
PolyPid	N/A	-241.96%	-126.91%

PolyPid has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.40	-$59M	-$0.97	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

Treace Medical Concepts has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 3 articles in the media. PolyPid's average media sentiment score of 1.54 beat Treace Medical Concepts' score of 1.14 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Treace Medical Concepts currently has a consensus target price of $4.77, suggesting a potential upside of 4.15%. PolyPid has a consensus target price of $11.67, suggesting a potential upside of 131.48%. Given PolyPid's stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

PolyPid beats Treace Medical Concepts on 9 of the 14 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$99.81M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-2.64	19.17	27.11	24.26
Price / Sales	N/A	838.79	589.18	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	7.30	4.22	10.73	6.29
Net Income	-$34.17M	$64.26M	$3.58B	$330.66M
7 Day Performance	-5.44%	-3.58%	-2.11%	-1.35%
1 Month Performance	9.09%	2.12%	3.27%	-0.64%
1 Year Performance	48.67%	20.35%	26.32%	19.08%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	3.5997 of 5 stars	$5.04 -3.6%	$11.67 +131.5%	+49.1%	$99.81M	N/A	N/A	80	Short Interest Decrease
ELMD Electromed	1.2735 of 5 stars	$45.70 -1.3%	$37.50 -17.9%	+141.0%	$383.45M	$71.75M	60.93	160	Positive News
CARL Carlsmed	2.4845 of 5 stars	$12.57 +2.3%	$18.75 +49.2%	N/A	$334.10M	$50.51M	N/A	100	Gap Up High Trading Volume
CV CapsoVision	3.2548 of 5 stars	$5.67 -14.2%	$8.50 +49.9%	+36.1%	$330.26M	$13.55M	N/A	90
SGHT Sight Sciences	3.5172 of 5 stars	$5.35 -2.4%	$8.14 +52.2%	+56.6%	$298.17M	$77.36M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors